Baxter secures conditional nod
Print Edition
China has approved Baxter International Inc’s US$4 billion bid for Sweden’s Gambro AB provided Baxter sells its global continuous renal replacement therapy (CRRT) business, among other conditions.
The US dialysis equipment maker must also end an outsourcing production deal in China with Japan’s Nipro Corp by March 31, 2016. The approval is subject to corporate monitors, the Ministry of Commerce said.
The conditional nod from China comes after Baxter secured European Union regulatory approval on July 22, having pledged to sell off the CRRT business, including supply deals and intellectual property rights. The CRRT division accounts for about 2 percent of Baxter’s renal product sales.
The deal, which Baxter unveiled in December, would make it the second-biggest manufacturer in the dialysis market, a sector set to expand in line with rising obesity and diabetes.
Baxter and Gambro compete against US-based DaVita Healthcare Partners Inc and Germany’s Fresenius Medical Care AG & Co, the biggest player in the hemodialysis market.
Baxter is buying Gambro from Swedish investment holding company Investor AB and its partly owned private equity company EQT.
China has approved mergers with conditions in many cases, but has only blocked one deal since its anti-monopoly law came into force in 2008. That was Coca-Cola’s bid to buy juice maker Huiyuan in 2009.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
